$APUS News

Apimeds Pharmaceuticals US' Subsidiary Mindwave Innovations Signs Three Agreements Between Sept. 24 And Oct. 4, 2026, To Build And Operate Dedicated Blockchain Networks For Clients In Climate Finance, Sports Media And Insurance

Why Is Apimeds Pharmaceuticals Stock Gaining Monday?

Apimeds’ Subsidiary MindWave Signs 12-Month Software Development And Technology Services Agreement With Flash Sports & Media To Build And Operate FlashChain

Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?

Apimeds Pharmaceuticals Enters First Amendment To Settlement Agreement On Sept. 10; Board To Consist Solely Of Four Members During Interim Period; Board To Expand To Seven Members After Interim Period; Amends Settlement Agreement With Inscobee Parties

Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On Aug 19, 2026; Freet Assigns All Apitox-Related Rights To Apimeds Pharmaceuticals; Receives 100% Korean Clinic Rights, 25% U.S. Royalty, 25% Overseas Revenue Participation For Apitox

Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

Apimeds Pharmaceuticals US Settles All Resolving Disputes With Inscobee Regarding Apimeds Business Combination With MindWave Innovations

Apimeds Pharmaceuticals Appoints Sungjoon Chae Co-CEO, Effective May 4

Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY

Apimeds Pharmaceuticals And Inscobee's Attempt To Oust Board And Officers Deemed Invalid Under Existing Merger Agreements; Vin Menon Continues To Serve As The Company's CEO; Erick Frim Continues To Serve As The Company's CFO

Apimeds Pharmaceuticals shares are trading lower. The company announced material breach of merger agreement by Inscobee, and prepares filing emergency action in Delaware Court of Chancery.

Apimeds Pharmaceuticals shares are trading lower. The company announced material breach of merger agreement by Inscobee, and prepares filing emergency action in Delaware Court of Chancery.

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

Apimeds Pharmaceuticals Announces Inscobee Violates Merger Agreement; Prepares Emergency Action To Be Filed In Delaware Court Of Chancery

Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Apimeds Pharmaceuticals And Lōkahi Therapeutics Secure FDA Type C Meeting To Discuss LT-100, Non-Opioid Biologic Candidate Being Developed For Osteoarthritis Treatment

Reported Earlier: Apimeds Pharma Announces Merger With MindWave Innovations; No Financial Terms Disclosed

Apimeds Pharmaceuticals Shares Resume Trade